China · Delayed Price · Currency is CNY Getein Biotech Statistics
Total Valuation
Getein Biotech has a market cap or net worth of CNY 4.61 billion. The enterprise value is 3.97 billion.
| Market Cap | 4.61B |
| Enterprise Value | 3.97B |
Important Dates
The last earnings date was Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
Getein Biotech has 507.15 million shares outstanding. The number of shares has decreased by -0.09% in one year.
| Current Share Class | 507.15M |
| Shares Outstanding | 507.15M |
| Shares Change (YoY) | -0.09% |
| Shares Change (QoQ) | +1.55% |
| Owned by Insiders (%) | 40.61% |
| Owned by Institutions (%) | 5.29% |
| Float | 284.30M |
Valuation Ratios
The trailing PE ratio is 20.66.
| PE Ratio | 20.66 |
| Forward PE | n/a |
| PS Ratio | 4.29 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 1.74 |
| P/FCF Ratio | 16.39 |
| P/OCF Ratio | 11.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.57, with an EV/FCF ratio of 14.12.
| EV / Earnings | 17.07 |
| EV / Sales | 3.78 |
| EV / EBITDA | 13.57 |
| EV / EBIT | 19.02 |
| EV / FCF | 14.12 |
Financial Position
The company has a current ratio of 3.21, with a Debt / Equity ratio of 0.14.
| Current Ratio | 3.21 |
| Quick Ratio | 2.37 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 1.32 |
| Debt / FCF | 1.43 |
| Interest Coverage | 20.44 |
Financial Efficiency
Return on equity (ROE) is 7.81% and return on invested capital (ROIC) is 12.21%.
| Return on Equity (ROE) | 7.81% |
| Return on Assets (ROA) | 3.74% |
| Return on Invested Capital (ROIC) | 12.21% |
| Return on Capital Employed (ROCE) | 7.46% |
| Weighted Average Cost of Capital (WACC) | 4.71% |
| Revenue Per Employee | 552,166 |
| Profits Per Employee | 119,495 |
| Employee Count | 1,947 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.83 |
Taxes
In the past 12 months, Getein Biotech has paid 18.17 million in taxes.
| Income Tax | 18.17M |
| Effective Tax Rate | 7.54% |
Stock Price Statistics
The stock price has increased by +10.05% in the last 52 weeks. The beta is 0.12, so Getein Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +10.05% |
| 50-Day Moving Average | 9.54 |
| 200-Day Moving Average | 8.74 |
| Relative Strength Index (RSI) | 41.08 |
| Average Volume (20 Days) | 15,370,166 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Getein Biotech had revenue of CNY 1.08 billion and earned 232.66 million in profits. Earnings per share was 0.46.
| Revenue | 1.08B |
| Gross Profit | 711.93M |
| Operating Income | 221.94M |
| Pretax Income | 241.03M |
| Net Income | 232.66M |
| EBITDA | 302.79M |
| EBIT | 221.94M |
| Earnings Per Share (EPS) | 0.46 |
Balance Sheet
The company has 1.36 billion in cash and 401.03 million in debt, with a net cash position of 956.80 million or 1.89 per share.
| Cash & Cash Equivalents | 1.36B |
| Total Debt | 401.03M |
| Net Cash | 956.80M |
| Net Cash Per Share | 1.89 |
| Equity (Book Value) | 2.93B |
| Book Value Per Share | 5.56 |
| Working Capital | 1.60B |
Cash Flow
In the last 12 months, operating cash flow was 416.41 million and capital expenditures -135.16 million, giving a free cash flow of 281.25 million.
| Operating Cash Flow | 416.41M |
| Capital Expenditures | -135.16M |
| Depreciation & Amortization | 83.02M |
| Net Borrowing | -203.06M |
| Free Cash Flow | 281.25M |
| FCF Per Share | 0.55 |
Margins
Gross margin is 66.22%, with operating and profit margins of 20.64% and 21.64%.
| Gross Margin | 66.22% |
| Operating Margin | 20.64% |
| Pretax Margin | 22.42% |
| Profit Margin | 21.64% |
| EBITDA Margin | 28.16% |
| EBIT Margin | 20.64% |
| FCF Margin | 26.16% |
Dividends & Yields
This stock pays an annual dividend of 0.18, which amounts to a dividend yield of 1.93%.
| Dividend Per Share | 0.18 |
| Dividend Yield | 1.93% |
| Dividend Growth (YoY) | -5.26% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 44.45% |
| Buyback Yield | 0.09% |
| Shareholder Yield | 2.01% |
| Earnings Yield | 5.05% |
| FCF Yield | 6.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 8, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jun 8, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |